Twist Bioscience (NASDAQ: TWST) Tops Revenue Target but Widens EPS Loss in Q2

Twist Bioscience shares gained 3.34% to $60.40 after the company reported fiscal Q2 2026 results, beating revenue expectations but posting a wider EPS loss than anticipated. The stock's price action reflects investor focus on top-line momentum over near-term profitability.

Q2 Fiscal 2026 At a Glance

• Revenue beat: Outperformed consensus expectations, demonstrating demand for synthetic biology and gene synthesis platforms
• EPS miss: Posted a wider loss than expected, continuing the company's unprofitable trajectory
• Gross margin: 51.62%, a strong level indicating robust pricing power and manufacturing efficiency
• Operating margin: -31.73%, reflecting heavy R&D and commercial spending to build market position

What Drove the Results

Twist's revenue beat reflects expanding demand for its DNA synthesis and clonal gene offerings, particularly as customers scale biotechnology applications. The company's recent announcement to expand clonal genes to include long and complex sequences positions it for deeper penetration in synthetic biology workflows. However, the company is operating at a significant loss, with a -19.56% net profit margin, typical for high-growth biotech firms investing heavily in product development and market expansion.

The -31.73% operating margin underscores Twist's capital-intensive model: the company is spending aggressively on R&D and sales infrastructure to capture market share in synthetic biology, a sector still in early adoption phases. This is a deliberate strategic choice rather than operational dysfunction.

Investor Takeaway

Twist Bioscience is a revenue growth story trading at a loss. The 51.62% gross margin proves unit economics work at scale, but the company must reach operating profitability to justify investment risk. The positive price reaction suggests the market prioritizes revenue acceleration over near-term losses. This is appropriate for growth-stage biotech, but investors must monitor cash burn rate and pathway to profitability closely. The stock suits venture-minded investors; conservative portfolios should wait for GAAP profitability or significantly reduced cash burn.